(Q34297505)

1 August 2017

1 reference

title

Alendronate: an update of its use in osteoporosis (English)

1 reference

1 August 2017

0 references

M Sharpe

1

1 reference

1 August 2017

S Noble

series ordinal

2

1 reference

1 August 2017

C M Spencer

series ordinal

3

1 reference

1 August 2017

publication date

1 January 2001

1 reference

1 August 2017

1 reference

1 August 2017

volume

61

1 reference

1 August 2017

issue

7

1 reference

1 August 2017

page(s)

999-1039

1 reference

Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial

1 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200161070-00010

Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group

21 January 2018

1 reference

12 December 2020

Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group

1 reference

12 December 2020

Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group

1 reference

12 December 2020

Effects of alendronate on gastric and duodenal mucosa

1 reference

12 December 2020

Clinical consequences of vertebral fractures

1 reference

12 December 2020

Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis

1 reference

12 December 2020

Are bisphosphonates useful in the management of corticosteroid induced osteoporosis in transplant patients?

1 reference

12 December 2020

Upper gastrointestinal ulceration with alendronate

1 reference

12 December 2020

Alendronate. A review of its pharmacological properties and therapeutic efficacy in postmenopausal osteoporosis

1 reference

12 December 2020

Guidelines for diagnosis and management of osteoporosis

1 reference

12 December 2020

Alendronate-associated esophagitis: endoscopic and pathologic features

1 reference

12 December 2020

Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group

1 reference

12 December 2020

Effectiveness of local delivery of alendronate in reducing alveolar bone loss following periodontal surgery in rats

1 reference

12 December 2020

Mortality after all major types of osteoporotic fracture in men and women: an observational study.

1 reference

12 December 2020

Esophagitis associated with the use of alendronate

1 reference

12 December 2020

Pharmacokinetics of alendronate

1 reference

12 December 2020

A new probable increasing cause of esophageal ulceration: alendronate

1 reference

12 December 2020

Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib.

1 reference

12 December 2020

[Alendronate-induced esophagitis. A report of 2 cases]

1 reference

12 December 2020

Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study

1 reference

12 December 2020

Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women

1 reference

12 December 2020

Use of oral corticosteroids and risk of fractures.

1 reference

12 December 2020

Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Introduction

1 reference

12 December 2020

Comparative tolerability of drug therapies for hypercalcaemia of malignancy

1 reference

12 December 2020

Mechanism of aminobisphosphonate action: characterization of alendronate inhibition of the isoprenoid pathway

1 reference

12 December 2020

Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs

1 reference

12 December 2020

Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group

1 reference

12 December 2020

Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial

1 reference

12 December 2020

Treatment of postmenopausal osteoporosis

1 reference

12 December 2020

An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae

1 reference

12 December 2020

Prevention of corticosteroid-induced bone loss with alendronate

1 reference

12 December 2020

Pre-existing fractures and bone mass predict vertebral fracture incidence in women

1 reference

12 December 2020

United Kingdom experience with alendronate and oesophageal reactions

1 reference

12 December 2020

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group

1 reference

12 December 2020

Symptomatic fracture incidence in elderly men and women: the Dubbo Osteoporosis Epidemiology Study (DOES)

1 reference

12 December 2020

Human osteoclast formation and activity in vitro: effects of alendronate.

1 reference

12 December 2020

Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis

1 reference

12 December 2020

Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients

1 reference

12 December 2020

1 reference

12 December 2020

Effects of alendronate on osteopenic postmenopausal Chinese women

1 reference

12 December 2020

Alendronate for the Treatment of Osteoporosis in Men

1 reference

12 December 2020

Calcitriol and alendronate combination treatment in menopausal women with low bone mass

1 reference

12 December 2020

Intramuscular clodronate in nonresponders to oral alendronate therapy for osteoporosis.

1 reference

12 December 2020

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

12 December 2020

Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis

1 reference

12 December 2020

Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy

1 reference

12 December 2020

Alendronate: preclinical studies

1 reference

12 December 2020

[Use of alendronate in osteoporosis--is it cost-effective?]

1 reference

12 December 2020

The efficacy and tolerability of alendronate in postmenopausal osteoporotic Chinese women: a randomized placebo-controlled study

1 reference

12 December 2020

Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group

1 reference

12 December 2020

Osteoporosis: epidemiology, diagnosis, and treatment.

1 reference

12 December 2020

Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. American College of Rheumatology Task Force on Osteoporosis Guidelines

1 reference

12 December 2020

Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial

1 reference

12 December 2020

Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures

1 reference

12 December 2020

Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation.

1 reference

12 December 2020

Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups

1 reference

12 December 2020

Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat.

1 reference

12 December 2020

Pharmacokinetics of intravenous alendronate

1 reference

12 December 2020

The effect of alendronate on bone mass after distal forearm fracture

1 reference

12 December 2020

Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women

1 reference

12 December 2020

Esophageal stricture associated with alendronate therapy

1 reference

12 December 2020

Esophageal irritation due to alendronate sodium tablets: possible mechanisms

1 reference

12 December 2020

Effects of 4-amino-1-hydroxybutylidene bisphosphonate on bone biomechanics in rats

1 reference

12 December 2020

Recommendations for the registration of new chemical entities used in the prevention and treatment of osteoporosis

1 reference

12 December 2020

Osteoporosis prevention and treatment

1 reference

12 December 2020

Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group

1 reference

12 December 2020

Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group

1 reference

12 December 2020

Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group

1 reference

12 December 2020

Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial

1 reference

12 December 2020

Bone mineral density reflects bone mass but also the degree of mineralization of bone: therapeutic implications

1 reference

12 December 2020

Prevalence of low femoral bone density in older U.S. women from NHANES III

1 reference

12 December 2020

Chronic glucocorticoid therapy-induced osteoporosis in patients with obstructive lung disease

1 reference

12 December 2020

Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial

1 reference

12 December 2020

Who are candidates for prevention and treatment for osteoporosis?

1 reference

12 December 2020

Effect of alendronate on fracture healing and bone remodeling in dogs

1 reference

12 December 2020

Treatment of patients with Paget's disease of bone

1 reference

12 December 2020

Management of male osteoporosis: report of the UK Consensus Group

1 reference

12 December 2020

What constitutes evidence for drug efficacy in osteoporosis?

1 reference

12 December 2020

Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis

1 reference

12 December 2020

Studies of the oral bioavailability of alendronate.

1 reference

12 December 2020

Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.

1 reference

12 December 2020

Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties

1 reference

12 December 2020

Alendronate in the treatment of Paget's disease of bone

1 reference

12 December 2020

Perspective. How many women have osteoporosis?

1 reference

12 December 2020

Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo

1 reference

12 December 2020

Effects of alendronate and hormone replacement therapy, alone or in combination, on bone mass in postmenopausal women with osteoporosis: a prospective, randomized study

1 reference

12 December 2020

A Bayesian analysis of bisphosphonate effects and cost-effectiveness in post-menopausal osteoporosis.

1 reference

12 December 2020

Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

12 December 2020

Long-term fracture prediction by bone mineral assessed at different skeletal sites

1 reference

12 December 2020

Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group

1 reference

12 December 2020

Upper gastrointestinal toxicity of alendronate

1 reference

12 December 2020

Effects of two intermittent alendronate regimens in the prevention or treatment of postmenopausal osteoporosis

1 reference

12 December 2020

Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group

1 reference

12 December 2020

Management of established osteoporosis

1 reference

12 December 2020

Bisphosphonates: from the laboratory to the clinic and back again

1 reference

12 December 2020

Prevalence of low femoral bone density in older U.S. adults from NHANES III.

1 reference

12 December 2020

Alendronate prevents bone loss in Chinese women with osteoporosis

1 reference

12 December 2020

Bisphosphonates act on rat bone resorption through the mediation of osteoblasts

1 reference

12 December 2020

Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis

1 reference

12 December 2020

Alendronate-induced esophagitis: case report of a recently recognized form of severe esophagitis with esophageal stricture--radiographic features.

1 reference

12 December 2020

Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis

1 reference

12 December 2020

Incidence of adverse oesophageal and gastric events in alendronate users

1 reference

12 December 2020

Long-term safety of the aminobisphosphonate alendronate in adult dogs. II. Histomorphometric analysis of the L5 vertebrae

1 reference

12 December 2020

The crippling consequences of fractures and their impact on quality of life

1 reference

12 December 2020

Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.

1 reference

12 December 2020

Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase

1 reference

12 December 2020

Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate

1 reference

12 December 2020

Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase

1 reference

12 December 2020

Short-term variations in bone remodeling biochemical markers: cyclical etidronate and alendronate effects compared

1 reference

12 December 2020

Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group

1 reference

12 December 2020

Diagnosis and treatment of glucocorticoid-induced osteoporosis

1 reference

12 December 2020

Esophagitis dissecans superficialis and alendronate: case report

1 reference

12 December 2020

The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates

1 reference

12 December 2020

1 reference

12 December 2020

Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders

1 reference

12 December 2020

A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. The Alendronate Phase III Osteoporosis Treatment Research Group

1 reference

12 December 2020

Decline in physical function following hip fracture

1 reference

12 December 2020

Association of prevalent vertebral fractures, bone density, and alendronate treatment with incident vertebral fractures: effect of number and spinal location of fractures. The Fracture Intervention Trial Research Group

1 reference

12 December 2020

Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate

1 reference

12 December 2020

Bisphosphonates inhibit IL-6 production by human osteoblast-like cells

1 reference

12 December 2020

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

12 December 2020

Alendronate gastric ulcers

1 reference

12 December 2020

Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women

1 reference

12 December 2020

The management of Paget's disease of bone

1 reference

12 December 2020

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

1 reference

12 December 2020

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

12 December 2020

Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers

1 reference

12 December 2020

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

1 reference

12 December 2020

Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy

1 reference

12 December 2020

[A cost-effectiveness analysis of alendronate compared to placebo in the prevention of hip fracture]

1 reference

12 December 2020

The prevention and treatment of osteoporosis

1 reference

12 December 2020

Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies

1 reference

12 December 2020

A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update.

1 reference

12 December 2020

Cellular and molecular mechanisms of action of bisphosphonates

1 reference

12 December 2020

Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones

1 reference

12 December 2020

The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates

1 reference

12 December 2020

Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro

1 reference

12 December 2020

Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms

1 reference

12 December 2020

Alendronate in the treatment of osteoporosis: a review of the clinical trials

1 reference

12 December 2020

Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial

1 reference

12 December 2020

Skeletal benefits of two years of alendronate treatment are similar for early postmenopausal Asian and Caucasian women

1 reference

12 December 2020

A placebo-controlled, single-blind study to determine the appropriate alendronate dosage in postmenopausal Japanese patients with osteoporosis. The Alendronate Research Group

1 reference

12 December 2020

Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. International Committee for Osteoporosis Clinical Guidelines.

1 reference

12 December 2020

A histopathological investigation on the effects of the bisphosphonate alendronate on resorptive phase following mucoperiosteal flap surgery in the mandible of rats

1 reference

12 December 2020

The prevention and treatment of osteoporosis

1 reference

12 December 2020

Mineralization of cancellous bone after alendronate and sodium fluoride treatment: A quantitative backscattered electron imaging study on minipig ribs

1 reference

12 December 2020

Alendronate inhibition of protein-tyrosine-phosphatase-meg1

1 reference

12 December 2020

Raloxifene: a review of its use in postmenopausal osteoporosis

1 reference

12 December 2020

Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals

1 reference

12 December 2020

Alendronate increases spine and hip bone mineral density in women with postmenopausal osteoporosis who failed to respond to intermittent cyclical etidronate

1 reference

12 December 2020

Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure

1 reference

12 December 2020

Severe oral ulcerations induced by alendronate

1 reference

12 December 2020

10.2165/00003495-200161070-00010

Identifiers

DOI

1 reference

Dimensions Publication ID

1 August 2017

1036893563

0 references

1 reference